Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Kavanaugh

Showing results (1-10 of 381) with videos related to

Pageof 39
Sort By:
Arthritis Care & Research|May 25, 2012
Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et alArthur Kavanaugh
Nature Clinical Practice. Rheumatology|August 26, 2006
Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?Arthur Kavanaugh
Nature Reviews. Rheumatology|November 22, 2017
Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development?Arthur Kavanaugh
Nature Reviews. Rheumatology|August 4, 2009
Therapy: Guidelines in rheumatology: quo vadis?Arthur Kavanaugh
Clinical and Experimental Rheumatology|October 20, 2012
Psoriatic arthritis: treat-to-targetArthur Kavanaugh
Current Rheumatology Reports|August 21, 2009
The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritisArthur Kavanaugh
Clinical and Experimental Rheumatology|June 26, 2010
Biologic agents in rheumatology: act IIArthur Kavanaugh
Arthritis and Rheumatism|April 5, 2002
Combination cytokine therapy: the next generation of rheumatoid arthritis therapy?Arthur Kavanaugh
Best Practice & Research. Clinical Rheumatology|September 18, 2007
Economic consequences of established rheumatoid arthritis and its treatmentArthur Kavanaugh
Current Opinion in Rheumatology|May 16, 2009
Infection prophylaxis in antirheumatic therapy: emphasis on vaccinationArthur Kavanaugh
Pageof 39

Showing results (1-10 of 381) with videos related to

Sort By:
Pageof 39
Arthritis Care & Research|May 25, 2012
Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et alArthur Kavanaugh
Nature Clinical Practice. Rheumatology|August 26, 2006
Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?Arthur Kavanaugh
Nature Reviews. Rheumatology|November 22, 2017
Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development?Arthur Kavanaugh
Nature Reviews. Rheumatology|August 4, 2009
Therapy: Guidelines in rheumatology: quo vadis?Arthur Kavanaugh
Clinical and Experimental Rheumatology|October 20, 2012
Psoriatic arthritis: treat-to-targetArthur Kavanaugh
Current Rheumatology Reports|August 21, 2009
The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritisArthur Kavanaugh
Clinical and Experimental Rheumatology|June 26, 2010
Biologic agents in rheumatology: act IIArthur Kavanaugh
Arthritis and Rheumatism|April 5, 2002
Combination cytokine therapy: the next generation of rheumatoid arthritis therapy?Arthur Kavanaugh
Best Practice & Research. Clinical Rheumatology|September 18, 2007
Economic consequences of established rheumatoid arthritis and its treatmentArthur Kavanaugh
Current Opinion in Rheumatology|May 16, 2009
Infection prophylaxis in antirheumatic therapy: emphasis on vaccinationArthur Kavanaugh
Pageof 39